Vera Therapeutics Scheduled to Present at November Investor Conferences
Vera Therapeutics, Inc. will be participating in two investor conferences, the Guggenheim 5th Annual Inflammation, Neurology, & Immunology Conference on November 6, 2023, and the 6th Annual Evercore ISI HealthCONx Conference on November 30, 2023. The company's management team will present and participate in one-on-one meetings at these conferences. Webcasts of the presentations will be available on the respective conference websites, and replays will be accessible on the Vera Therapeutics website for 30 days.
10/30/2023 - 08:00 AM
BRISBANE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present and participate in one-on-one meetings at the following investor conferences, as detailed below:
Guggenheim 5th Annual Inflammation, Neurology, & Immunology Conference Format: Fireside Chat Date and Time: Monday, November 6, 2023, 9:50 – 10:20 AM EST Webcast: https://guggenheim.metameetings.net
6 th Annual Evercore ISI HealthCONx Conference Format: Fireside Chat Date and Time: Thursday, November 30, 2023, 10:50 – 11:10 AM EST Webcast: https://wsw.com/webcast/evercore39/vera
A replay of the presentations will be available for 30 days and can be accessed by visiting the “Investor Calendar ” section of the Vera Therapeutics website.
About Vera Therapeutics Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunologic diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B Lymphocyte Stimulator (BLyS) and A Proliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit www.veratx.com .
For more information, please contact:
Investor Contact: Joyce Allaire LifeSci Advisors 212-915-2569jallaire@lifesciadvisors.com
Media Contact: Minyan Weiss Uncapped Communications, Inc. Minyan.Weiss@uncappedcommunications.com
Vera Therapeutics will be participating in the Guggenheim 5th Annual Inflammation, Neurology, & Immunology Conference on Monday, November 6, 2023.
Vera Therapeutics will be participating in the 6th Annual Evercore ISI HealthCONx Conference on Thursday, November 30, 2023.
The webcast of the Guggenheim conference can be accessed at https://guggenheim.metameetings.net, and the webcast of the Evercore ISI conference can be accessed at https://wsw.com/webcast/evercore39/vera.
The replays of the presentations will be available for 30 days.
The replays of the presentations can be accessed in the 'Investor Calendar' section of the Vera Therapeutics website.